Celularity vs ProQR Therapeutics
CELU and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and PRQR compare
ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −58.1% for Celularity).
ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −246% at Celularity.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | PRQR |
|---|---|---|
| Size and price | ||
| Market cap | $24.4M | – |
| Share price | $0.751 | $1.26 |
| Change, 1 year | −57.6% | −41.7% |
| Change, 5 years | −98.9% | −83.8% |
| Beta (5Y) | 1.96 | 1.25 |
| Employees | 115 | 59 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | – |
| Growth | ||
| Revenue growth (TTM) | −58.1% | 11.4% (better) |
| Revenue growth, 5Y average | 13.2% | – |
| Profitability | ||
| Gross margin | 19.2% | – |
| Operating margin | −264% | −233% (better) |
| Net margin | −246% | −229% (better) |
| FCF margin | – | −273% |
| Return on equity | – | −57.4% |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Current ratio | 0.11 | 3.49 (better) |
| Altman Z-score | −16.46 | – |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 6.8% | 57.6% |
| Held by insiders | – | 37.8% |
| Insider net buying, 12 months | – | $1.3M |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.